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ABSTRACT 
Glaucoma is the second cause of irreversible blindness, and the Primary Open Angle Glaucoma (POAG) subtype is the 
most common type of glaucoma. It has been shown that genetic mutations increase the risk of POAG used for early 
detection. The aim of the current study was to determine the association between genetic variations of Myocilin (MYOC) 
gene and susceptibility to POAG in the Iranian population. This case-control study was conducted on patients with POAG, 
referred to Khatam-al Anbia Eye Hospital, Mashhad, Iran. The control group was selected from healthy patients with a 
refractive disorder, who had referred to this hospital. After extracting the DNA from the whole blood sample, the 
Polymerase Chain Reaction-Single-Strand Conformation Polymorphisms (PCR-SSCP) method was used to discriminate 
variability in sequences in three exons of MYOC gene locus, known as GLC1A. Clinical characteristics of the subjects, 
comprised of visual acuity, Cup to Disc Ratio (CDR), and Intra-Ocular Pressure (IOP) were statistically compared between 
the wild and mutant type of the MYOC gene using independent samples t-test, Chi-square, and logistic regression test 
with SPSS version 15.0 software. P-values of < 0.05 were considered significant. One hundred and forty participants 
(75.1% males) were studied in two groups of case (n = 70) and control (n = 70). The frequency of mutant alleles in 
patients and healthy groups was statistically significant (40% versus 11.5%, Odd’s Ratio (OR): 5.1, CI 95% for OR: 2.1 to 
12.4, P-value < 0.001). Also, the detected mutation in the case group was significantly higher in exon 1 and 3 (15.7% 
versus 0%, P-value = 0.001, and 11.5% versus 2.8%, P-value = 0.049, respectively). Based on the result of the current 
study, it seems that the MYOC gene polymorphisms increased the risk of POAG in the Iranian population. 
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INTRODUCTION
Glaucoma refers to a group of diseases associated with 
optic neuropathy and decreased vision. Glaucoma affects 
more than 65 million people, worldwide, and is the 
second most common cause of blindness [1]. By affecting 
70% of glaucomatous patients among Caucasians, 
Primary Open Angle Glaucoma (POAG) has been 
considered as the most common type of glaucoma at age 
40 years and older [2]. Genetic analysis has identified 
more than ten loci linked to POAG, attesting to its high 
genetic heterogeneity [3-6]. Genes at three of these loci 
have been identified, including Myocilin, Optineurin, and 
WD Repeat-containing protein 36 (WDR36). Mutations in 
Myocilin (MYOC) have been observed more frequently 
than mutations in OPTN and WDR36, although most 
cases of glaucoma do not involve these genetic 
mutations. Furthermore, MYOC or Trabecular Meshwork 
Inducible Glucocorticoid Response (TIGR) is a protein, 
which is encoded by the MYOC gene in humans. 
Mutations in MYOC are a major cause of glaucoma and 
have been discovered in 3% to 4% of patients with POAG 
(7). The MYOC gene locus (known as Glaucoma 1A or 
GLC1A), was mapped to chromosome 1q23. Overall, 90% 
of the mutations were located on exon 3, which contains 
the olfactomedin homology [7, 8]. 
According to Souzeau’s study, MYOC gene mutations are 
associated with disease severity and are more commonly 
found in advanced POAG [9]. Elahi et al. studied 
mutations of the MYOC gene in Primary Congenital 
Glaucoma (PCG) in the Iranian population and found it as 
an insignificant cause [10]. Therefore, the current study 
was designed to prove or rule out the disease causative 
role of MYOC gene mutations, using the Polymerase 
Chain Reaction-Single Strand Conformation 
Polymorphism (PCR-SSCP) method, among POAG 
patients of Khorasan district. This study also compared 
clinical features between the mutant and the wild group 
in the study population. Lack of information about 
genetic susceptibility of POAG in the Iranian population 
and ethnical differences were reasons for performing the 
current study. 
METHODS 
In this case-control study, 70 patients with POAG, who 
were referred to Khatam-Al Anbia eye hospital and 70 
healthy blood donors were enrolled from the Khorasan 
province of Iran in a study (project code:86626-MUMS) 
from January 2009 to September 2012. Simple non-
probability sampling method was used to select the 
healthy control group and patients, who were referred to 
Khatam-Al Anbia eye hospital. This hospital is a tertiary 
center of Khorasan province, Iran, and participants also 
referred from other provinces. 
The diagnosis of POAG was based on elevated Intraocular 
Pressure (IOP), abnormal perimetry changes, and an 
increased Cup to Disc Ratio (CDR) in the presence of a 
normal gonioscopy, which were diagnosed by an 
ophthalmology specialist. The exclusion criteria of the 
study were as follows: history of ocular trauma, uveitis, 
abnormal gonioscopy, and history of previous eye 
surgery or laser iridectomy. Slit lamp and fundus 
examination were done for all patients and visual acuity, 
Cup to Disc Ratio (CDR), and IOP were recorded by 
Goldman applanation tonometry (Haag Striet, Swiss) [2]. 
The controls (without a history of glaucoma) were 
recruited from the General Ophthalmology Clinic of the 
hospital, and were detected to have no ocular or 
systemic diseases, other than simple refractive errors.  
An informed consent was signed by all patients and 
controls. Age, gender, uncorrected Visual Acuity (VA), 
IOP and CDR of patients, and the healthy group were 
recorded for analysis. 
Peripheral blood sample of each subject was obtained, 
and by using a commercially available kit (Biogene 
Company, Iran), according to the manufacturer’s 
instructions, genomic DNA was extracted. Genotyping of 
MYOC gene polymorphism was done by the PCR-SSCP 
method, as explained in previous studies [11, 12]. Three 
exons of the MYOC gene were amplified by the 
Polymerase Chain Reaction (PCR), using the single-strand 
primer for exons (Table 1). 
The sizes of the single-stranded fragments were 
compared by electrophoresis on a neutral 
polyacrylamide gel. The proliferated bands were 
detected by silver staining, and the results were 
interpreted. 
This study received ethical approval from the ethics 
committee of Mashhad University of Medical Sciences 
and written informed consent was signed by all study 
subjects. Patients’ name and results of the test were 
secured by a code. 
The chi-square and Fisher’s exact test were used to 
compare genotypic frequencies of the study groups. 
Moreover, independent samples t-test and logistic 
regression test were performed. Statistical analysis was 
conducted using the SPSS software for Windows (version 
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15.0, SPSS, Chicago, IL). P-values of less than 0.05 
difference were considered significant. 
RESULTS 
Seventy patients, including 52 (75.1%) males and 18 
(24.9%) females, with mean ± Standard Deviation (SD) 
age of 56.7 ± 18.6 years and 70 controls, including 35 
(50%) male and 35 (50%) females, with mean ± SD age of 
27.2 ± 6.9 years were enrolled in the study. The results of 
initial and final IOP, CDR, and VA studies revealed that 
IOP decreased significantly due to medical and surgical 
intervention in the patient group (P-value < 0.001). In 
spite of significantly decreased IOP, the CDR was 
increased significantly (P-value < 0.001). Comparison of 
initial and final VA of the patients showed that right eye 
vision was not different (P-value = 0.036) while the left 
eye vision was significantly decreased between initial and 
final VA measurement (P-value = 0.005). 
 
Table 1. Myocilin Gene Primers, pair’s Sequences and Length of Amplified Sequences 
Primer Name Primer Sequence Amplified Sequence Length 
Myo-1Fa 5'-CCTCACGTGGCCACCTCTGTC-3' 554 bp 
Myo-1Ra 5'-GGTTTCCAGCTGGTCCCGCTC-3' 554 bp 
Myo-1Fb 5'-ATAACTTACAGAGAGACAGCAGC-3' 494 bp 
Myo-1Rb 5'-CTCTAGGAGAAAGGGCAGGCAG-3' 494 bp 
Myo-2F 5'-GCCGGCAGCCTATTTAAATGTC-3' 404 bp 
Myo-2R 5'-CCTGCTCTGACAAGGGAACAG-3' 404 bp 
Myo-3Fa 5'-GCTGTCACATCTACTGGCTCTG–3' 736 bp 
Myo-3Ra 5'-GTCATAAGCAAAGTTGACGGTAGC-3' 736 bp 
Myo-3Fb 5'-TGGCACCTTGTACACCGTCAGC-3' 766 bp 
Myo-3Rb 5'-CTCTTAAGCAAAGATTCCCACAAAG–3' 766 bp 
Myo: Myocilin, F: Forward primer, R: Reverse primer, bp: base pair. 
 
Genetic Analysis 
Two loci in exon 1, one locus in exon 2, and two loci in 
exon 3 were evaluated for MYOC gene mutation. The 
result of genotyping showed that there was a statistically 
significant difference in the MYOC gene mutation 
between the study groups (40% versus 11.5%, 
respectively, P-value < 0.001, OR = 5.1, CI95% for OR: 2.1 
to 12.4). Moreover, the frequency of mutations in exon 
1a and 3a were significantly higher in the patient group 
compared to the control group (15.7% versus 0% P-value 
= 0.001, OR: 27.2, CI95% for OR: 1.5 to 472.2 and 11.5% 
versus 2.8%, P-value = 0.049, OR: 4.3, CI95% for OR: 0.9 
to 21.4, respectively) yet the difference between the 
frequency of 1b and 3b exon mutations was insignificant. 
Also, there was no frequency difference between the 
study group in exon 2 (Table 2). 
 
Table 2. Genetic Variation Between Patients and the Control Group 
Locus of mutation Mutation Patients Controls P value* *P value (Adjusted by age) OR* CI 95 for OR 
1a Positive 11 (15.7) 0 (0) 0.001 0.006 27.2 1.5 to 472.2 
 Negative 59(84.3) 70 (100) - - -  
1b Positive 6 (8.5) 2 (2.8) 0.14 0.07 3.1 0.6 to 16.3 
 Negative 64 (91.5) 68(97.2) - - - - 
2 Positive 0 (0) 0 (0) - - - - 
 Negative 70 (100) 70 (100) - - - - 
3a Positive 8 (11.4) 2 (2.8) 0.049 0.12 4.3 0.9 to 21.4 
 Negative 62(88.6) 68(97.2)     
3b Positive 9 (12.9) 4 (5.7) 0.14 0.28 2.4 0.7 to 8.3 
 Negative 61(87.1) 66(94.3)     
Data are presented as No (%). n: number; %: percentage; OR: odds ratio; CI: Confidence interval. 
*Statistically analyzed using Chi-Square, univariate general linear models and logistic regression tests.  
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Genetic Variation and Clinical Course 
The visual acuity, IOP, and CDR were compared between 
wild-type and mutant type of the studied gene in the 
patient group. The mean ± SD of VA (Log Mar) in all cases 
was 0.43 ± 0.45 for the right eye and 0.57 ± 0.61 for the 
left eye of patients, who carried the wild-type gene. 
Furthermore, mean ± SD of VA (Log Mar) was 0.48 ± 0.48 
and 0.36 ± 0.43 for the right and left eyes, respectively, in 
patients with the mutant type of the selected gene. 
These differences were not statistically significant 
between groups (P-value = 0.7 for the right eye and P-
value = 0.17 for the left eye) (Table 3). 
The mean ± SD of the recorded IOP under topical anti-
glaucoma drops in all cases was 15.9 ± 13.5 (mmHg) and 
22.7 ± 10.1 (mmHg) for the right and left eyes in the 
patients carrying wild-type genotype and also 22.5 ± 1.5 
(mmHg) and 19.9 ± 9.1 (mmHg) for the right and left eye 
of the patients with mutant type genotype, respectively. 
These differences were not significant between the 
groups (P-value = 0.34 for the right eye and P-value = 
0.32 for the left eye). Table 4 represents the comparison 
of IOP between mutant and wild-type genotypes in each 
exon, separately. 
Overall, mean ± SD of CDR was 0.7 ± 0.27 and 0.66 ± 0.26 
for the right and left eyes of patients carrying wild-type 
genotype, respectively. In addition, mean ± SD of CDR 
was 0.75 ± 0.23 and 0.65 ± 0.24 for the right and left eyes 
in patients with the mutant type. The cup to disc ratio 
differences between studied groups were not statistically 
significant (P-value = 0.34 for the right eye and P-value = 
0.32 for the left eye) (Table 5). 
 
Table 3. Comparing the Visual Acuity (Log MAR) between Participants Carrying the Mutant and Wild-type Sequence 
Site of changes Mutant 
Mean ± SD 
Wild type 
Mean ± SD 
P value * 
1a    
Right eye 0.66 ± 0.65 0.41± 0.41 0.15 
Left eye 0.37 ± 0.60 0.51 ± 0.55 0.51 
1b    
Right eye 0.64 ± 0.69 0.43 ± 0.43 0.33 
Left eye 0.72 ± 0.66 0.47 ± 0.51 0.35 
3a    
Right eye 0.78 ± 0.61 0.41 ± 0.43 0.09 
Left eye 0.53 ± 0.65 0.49 ± 0.55 0.86 
3b    
Right eye 0.28 ± 0.25 0.47 ± 0.48 0.30 
Left eye 0.40 ± 0.34 051 ± 0.58 0.59 
VA: visual acuity; Log MAR: Logarithm of the Minimum Angle of Resolution; SD: Standard Deviation. * Statistically analyzed using Independent T test. 
 
Table 4. Comparing the Intraocular Pressure between Participants Carrying Mutant and Wild-type Sequence 
Site of changes Mutant IOP (Mean ± SD) Wild type IOP (Mean ± SD) P value * 
1a    
Right eye 18.38 ± 6.78 25.69 ± 13.68 0.14 
Left eye 18.38 ± 5.26 22.18 ± 10.86 0.33 
1b    
Right eye 27.0 ± 8.88 24.48 ± 13.53 0.68 
Left eye 27.80 ± 13.04 21.08 ± 9.98 0.16 
3a    
Right eye 24.83 ± 17.56 24.68 ± 12.79 0.97 
Left eye 22.33 ± 6.71 21.58 ± 10.70 0.86 
3b    
Right eye 20.13 ± 9.94 25.41 ± 13.53 0.29 
Left eye 18.50 ± 10.67 22.16 ± 10.28 0.35 
  IOP: intraocular pressure; mmHg: millimeter of mercury; SD: Standard Deviation. * Statistically analyzed using Independent T test.  
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Table 5. Comparing the Cup to Disc Ratio between Participants Carrying the Mutant and Wild type Sequence 
Site of changes Mutant CDR 
Mean ± SD 
Wild type CDR 
Mean ± SD 
P value * 
1a    
Right eye 0.77 ± 0.23 0.70 ±0.26 0.48 
Left eye 0.71 ± 0.21 0.64 ± 0.26 0.51 
1b    
Right eye 0.27 ± 0.30 0.71 ± 0.25 0.96 
Left eye 0.64 ± 0.32 0.65 ± 0.25 0.87 
3a    
Right eye 0.75 ± 0.27 0.71 ± 0.25 0.73 
Left eye 0.65 ± 0.28 0.65 ± 0.25 0.94 
3b    
Right eye 0.75 ± 0.18 0.70 ± 0.26 0.68 
Left eye 0.63 ± 0.22 0.66 ± 0.26 0.81 
Data in table are presented as Mean ± SD. CDR: cup to disc ratio; SD: Standard Deviation. * Statistically analyzed using Independent T test.  
 
DISCUSSION
The current study was designed to prove or rule out the 
disease causative role of the MYOC gene mutations by 
screening the MYOC gene, using SSCP analysis and 
comparing clinical features among POAG patients in the 
Khorasan district. The SSCP analysis was used to screen 
healthy and POAG subjects in every three exons of the 
GLC1A gene (MYOC gene). The results revealed that the 
frequency of MYOC gene polymorphisms in patients was 
higher than the control group. A possible explanation for 
the aggressive nature and weak response to treatment of 
these patients is the inheritance of the mentioned 
polymorphisms. According to the obtained results, the 
mean CDR was 0.7 in spite of full medication in nearly all 
patients. On the other hand, although all of the patients 
were Iranian, they were from different ethnicities and 
districts, as Khatam-Al Anbia eye hospital is a referral 
center in the east of Iran. 
Genetic factors are responsible for the progression and 
response to treatment in many diseases. In glaucoma, 
genetic factors are important in disease progression or 
stability, yet due to variation in the results of studies on 
different ethnic groups and societies, there is no 
agreement on the role of genetic factors in POAG 
susceptibility [3-6]. 
Several mutations have been reported in different ethnic 
groups for POAG. In 1999, Finger et al. reported that the 
mean frequency of POAG mutations in different ethnic 
groups was 3% [8]. Based on the current study, the 
frequency of MYOC gene polymorphism was higher than 
other populations and these differences were statistically 
significant at the 1a and 3a position. So far, two other 
studies on genetic susceptibility of glaucoma have been 
done on the Iranian population. One of these studies 
screened the common CYP1B1 mutations in Iranian 
POAG patients, which found CYP1B1, as an effective 
cause in POAG subjects, mainly in juvenile glaucoma. 
Seven patients with POAG (11.1%) were carriers of 
CYP1B1 mutations whereby the majority, including five, 
were in the juvenile-onset group (5/21) and the rest were 
in the late-onset group (2/42) [13]. Another study by 
Elahi et al. was conducted to test the frequency of MYOC 
gene mutations in Iranian patients with PCG, in which 
none of the patients had mutations in this gene. The 
authors concluded that in Iranian PCG patients, the 
mutation of this gene could not be the main cause [10]. 
The influence of the disease course and response to 
treatment by the presence or the type of mutation has 
been reported in several studies. n the study of Graul et 
al., the rates of laser trabeculoplasty and surgery in 
POAG patients with a GLN368STOP MYOC mutation were 
similar with POAG patients without this mutation [14]. In 
contrast, in another study by Craig et al., the rate of 
filtration surgery in glaucoma patients with GLN368STOP 
mutations was higher than those without the mutations 
[15]. 
Souzeau et al. compared advanced glaucoma with less 
advanced cases and found a higher frequency of MYOC 
mutations in an Australasian disease registry. The 
frequency of MYOC mutations in glaucomatous patients 
with severe visual field loss was significantly higher than 
early glaucomatous patients [9]. In contrary, based on 
the results of the current study, there was no association 
between clinical signs of glaucoma and the presence of 
MYOC gene polymorphisms, according to the PCR-SSCP 
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method. The IOP, CDR, and VA were not statistically 
different between the participants carrying wild-type and 
mutant type of the MYOC gene. Therefore, the findings 
may question the theory of the effect of genetic factors 
on the course of POAG. However, to reach more 
conclusive results more studies with larger sample sizes, 
stronger design, and racial diversity are needed. 
Furthermore, for more precise estimation of the 
association between gene mutations and susceptibility of 
diseases, the obtained results by PCR-SSCP should be 
confirmed by gene sequencing. Moreover, small sample 
size and not-completed complementary demographic 
data of case and control participants were other 
limitations of the present study. Also, the difference in 
patient and control group’s age was another limitation of 
the present study.  
CONCLUSIONS 
The results of the current study showed that there was a 
statistically significant difference in MYOC gene mutation 
between patient and healthy groups, especially in exon 
1a and 3a. Also, there was no association between 
clinical signs of the disease and the presence of MYOC 
gene polymorphisms. The findings should be confirmed 
by more specific methods, such as gene sequencing. 
Because of the role of genetic variations in increasing 
susceptibility to glaucoma, it is necessary to find other 
variations and mutations as well. 
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